Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab for cytokine storm in severe COVID-19 pneumonia
2020-001255-40Phase 2Completed
- Sponsor
- Clínica Universidad de Navarra
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of sarilumab in coronavirus disease 2019 (COVID-19), pneumonia and cytokine release syndrome (CRS), sponsored by Clínica Universidad de Navarra. Primary endpoint: Change in 7-point ordinal clinical severity scale. Started Apr 2020; status: completed.
02
Drugs
sarilumab
03
Conditions
coronavirus disease 2019 (COVID-19)pneumoniacytokine release syndrome (CRS)
Beyond the preview
Go deeper on 2020-001255-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001255-40.